Fat and cardiotoxicity in hereditary pulmonary hypertension.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Pulmonary Hypertension and Right Ventricle: A Pathophysiological Insight.Clinical Medicine Insights. Cardiology · 2024
   Review
2. Molecular mechanisms of right ventricular dysfunction in pulmonary arterial hypertension: focus on the coronary vasculature, sex hormones, and glucose/lipid metabolism.Cardiovascular diagnosis and therapy · 2020
   Review
3. Role of oxidized lipids in pulmonary arterial hypertension.Pulmonary circulation · 2016
   Review
4. Update in Pulmonary Vascular Diseases 2014.American journal of respiratory and critical care medicine · 2015
   Review

Corrections and comments

• Comment on
  Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension.2014

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as